A case of refractory chronic spontaneous urticaria treated with omalizumab

Humayun Shahzad


Chronic spontaneous urticaria (CSU) is a chronic and refractory dermatosis. Omalizumab is a relatively new addition to CSU therapeutic armamentarium. We present a 52-year-old male having symptoms of chronic spontaneous urticaria (CSU) of moderate severity for last 15 years. He was on regular H1 antagonist and mast cell stabilizers was started with 300 mg omalizumab on monthly basis, Urticaria activity score started improving after second month. Patient is still using H1 antagonist but not regularly but with a liberal lifestyle as compared to previously.


Chronic spontaneous urticaria, omalizumab

Full Text:



Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120:979-81.

Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007;99:190-3.

Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569-73.

Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM et al. EAACI/GA2LEN/ EDF guideline: management of urticaria. Allergy. 2006;61:321-31.


  • There are currently no refbacks.

ISSN: 1560-9014